Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases-Reference-Cited by-同舟云学术

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

Published:2015-07-31 Issue:1 Volume:90 Page:91-100
ISSN:1552-4949
Container-title:Cytometry Part B: Clinical Cytometry
language:en
Short-container-title:Cytometry

Author:

Pojero Fanny¹²,Flores-Montero Juan¹,Sanoja Luzalba¹,Pérez José Juan³,Puig Noemí³,Paiva Bruno⁴,Bottcher Sebastian⁵,van Dongen Jacques J. M.⁶,Orfao Alberto¹,

Affiliation:

1. Centro de Investigación del Cáncer (Instituto de Biología Molecular y Celular del Cáncer, CSIC-USAL); Instituto Biosanitario de Salamanca (IBSAL), Servicio General de Citometría y Departamento De Medicina (NUCLEUS), Universidad de Salamanca (Salamanca); Spain

2. Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi; Universita’ degli Studi di Palermo; Palermo Italy

3. Departmento de Hematología; Hospital Universitario de Salamanca, IBSAL; IBMCC (USAL-CSIC); Salamanca Spain

4. Clínica Universidad de Navarra; Centro de Investigaciones Médicas Aplicadas (CIMA); Pamplona Spain

5. Second Department of Medicine; University Hospital of Schleswig-Holstein; Campus Kiel Kiel Germany

6. Department of Immunology, Erasmus MC; University Medical Center Rotterdam (Erasmus MC); Rotterdamthe Netherlands

Funder

the Instituto de Salud Carlos III (Ministry of Economy and Competitivity, Madrid, Spain)

EuroFlow Consortium, the International Myeloma Foundation-Black Swan Research Initiative, the Red Temática de Investigación Cooperativa en Cáncer (RTICC)

Publisher

Wiley

Subject

Cell Biology,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cyto.b.21269/fullpdf

Reference27 articles.

1. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation;Paiva;Blood,2008

2. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy;Mateo;J Clin Oncol,2008

3. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients;Paiva;Blood,2009

4. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients;Paiva;Haematologica,2009

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma;International Journal of Laboratory Hematology;2024-09-12

2. Establishing Monoclonal Gammopathy of Undetermined Significance as an Independent Pre-Disease State of Multiple Myeloma Using Raman Spectroscopy, Dynamical Network Biomarker Theory, and Energy Landscape Analysis;International Journal of Molecular Sciences;2024-01-26

3. Flow Cytometry in Diagnosis, Prognostication, and Monitoring of Multiple Myeloma and Related Disorders;Clinics in Laboratory Medicine;2023-09

4. Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab;American Journal of Clinical Pathology;2023-08-01

5. Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity;Science Translational Medicine;2023-07-19